Additional file 1 of A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
posted on 2021-02-26, 04:34authored byHeng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang, Changcheng Zheng, Xuliang Shen, Qi Hu, Jing Liu, Jie Jin, Jianmin Luo, Yun Zeng, Sujun Gao, Xiaohui Zhang, Xin Zhou, Qingzhi Shi, Ruixiang Xia, Xiaobao Xie, Zhongxing Jiang, Li Gao, Yuansong Bai, Junye Xiong, Runzi Li, Jianjun Zou, Ting Niu, Renchi Yang, Yu Hu
Additional file 1: Table S1. Investigators per site. Table S2. Dose adjustments of hetrombopag during the double-blind treatment period and open-label treatment period. Table S3. Dose adjustments of eltrombopag for patients in the Placebo-eltrombopag group during the double-blind treatment period and open-label treatment period. Table S4. Platelet responses (platelet counts ≥ 50 × 109/L at week 8) were observed across all subgroups of baseline platelet counts, sex, age, and splenectomy status. Table S5. Proportion of responders at different time points within 8 weeks after treatment.